Sønderstrup G, McDevitt H
Department of Microbiology and Immunology, Stanford University School of Medicine, CA 94305-5124, USA.
Immunol Rev. 1998 Aug;164:129-38. doi: 10.1111/j.1600-065x.1998.tb01215.x.
MHC class II molecules function by selective binding of antigenic peptides, thereby both shaping the T-cell receptor (TCR) repertoire in the thymus and influencing presentation of immunogenic peptides to CD4+ T cells in the periphery. The strong association between a number of human autoimmune diseases (type 1 diabetes, rheumatoid arthritis, and multiple sclerosis) and certain HLA-DR/DQ alleles suggests that it may be possible to alter pathological autoimmune responses by deliberate introduction of autoantigenic peptides in a "tolerogenic" manner. Since there are likely to be differences in epitope selection and epitope spreading in different patients over time, this approach requires identification of all the immunogenic CD4+ T-cell epitopes (dominant, subdominant, or cryptic) of an autoantigen which elicit T-cell responses restricted to the HLA-DR/DQ alleles predisposing to these autoimmune diseases. This paper describes a new approach for the identification of immunogenic peptide epitopes of human autoantigenic proteins using HLA-DR and DQ transgenic mice. These mice are engineered to select a full TCR repertoire which can identify immunogenic peptide epitopes similar or identical to human subjects of the same HLA-DR/DQ genotype. This experimental system also allows comparison of autoantigenic immune responses restricted to disease-susceptible and disease-resistant HLA-DR/DQ alleles.
MHC II类分子通过选择性结合抗原肽发挥作用,从而在胸腺中塑造T细胞受体(TCR)库,并在外周影响免疫原性肽向CD4+ T细胞的呈递。许多人类自身免疫性疾病(1型糖尿病、类风湿性关节炎和多发性硬化症)与某些HLA-DR/DQ等位基因之间的强关联表明,有可能通过以“耐受性”方式有意引入自身抗原肽来改变病理性自身免疫反应。由于不同患者随时间推移在表位选择和表位扩展方面可能存在差异,这种方法需要鉴定自身抗原的所有免疫原性CD4+ T细胞表位(显性、亚显性或隐蔽性),这些表位引发的T细胞反应受易患这些自身免疫性疾病的HLA-DR/DQ等位基因限制。本文描述了一种使用HLA-DR和DQ转基因小鼠鉴定人类自身抗原蛋白免疫原性肽表位的新方法。这些小鼠经过基因工程改造,以选择一个完整的TCR库,该库能够识别与具有相同HLA-DR/DQ基因型的人类受试者相似或相同的免疫原性肽表位。该实验系统还允许比较受疾病易感和抗病HLA-DR/DQ等位基因限制的自身抗原免疫反应。